Brief: Standard Biotools Reports Fourth Quarter Results And Provides 2023 Business Outlook

Standard BioTools

14/02/2023 21:39

Feb 14 (Reuters) - Standard BioTools Inc  LAB.O :
    * STANDARD BIOTOOLS REPORTS FOURTH QUARTER AND FULL YEAR
2022
FINANCIAL RESULTS AND PROVIDES 2023 BUSINESS OUTLOOK
    * STANDARD BIOTOOLS- SEES NON-GAAP OPERATING EXPENSE
REDUCTIONS OF
ABOUT $30 MILLION FOR 2023, ABOUT 3,100 BASIS POINT IMPROVEMENT
IN OPERATING MARGIN
    * STANDARD BIOTOOLS INC - FY 2022 GAAP REVENUES WERE $97.9
MILLION
COMPARED TO $130.6 MILLION IN 2021
    * STANDARD BIOTOOLS INC - FOR 2023, STANDARD BIOTOOLS
EXPECTS
FLAT-TO-MODERATE GROWTH IN CORE PRODUCT AND SERVICE REVENUES
RELATIVE TO 2022
    * STANDARD BIOTOOLS INC - GAAP PRODUCT AND SERVICES MARGINS
ARE
CURRENTLY EXPECTED TO INCREASE TO 52%-55% BY Q4 OF 2023
    * STANDARD BIOTOOLS INC - NON-GAAP PRODUCT AND SERVICES
MARGINS
ARE EXPECTED TO INCREASE TO 65%-68% BY Q4 OF 2023

Source text for Eikon:  ID:nGNX4t7gzV 
Further company coverage:  LAB.O 
 ((Reuters.Briefs@thomsonreuters.com;))